1. Home
  2. PRT vs FEMY Comparison

PRT vs FEMY Comparison

Compare PRT & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PermRock Royalty Trust Trust Units

PRT

PermRock Royalty Trust Trust Units

HOLD

Current Price

$2.95

Market Cap

41.4M

Sector

Energy

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.43

Market Cap

37.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRT
FEMY
Founded
2017
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.4M
37.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PRT
FEMY
Price
$2.95
$0.43
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.50
AVG Volume (30 Days)
52.3K
577.6K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
12.70%
N/A
EPS Growth
N/A
44.71
EPS
N/A
N/A
Revenue
N/A
$2,293,313.00
Revenue This Year
N/A
$183.83
Revenue Next Year
N/A
$196.80
P/E Ratio
$7.78
N/A
Revenue Growth
N/A
40.77
52 Week Low
$2.61
$0.31
52 Week High
$4.28
$1.29

Technical Indicators

Market Signals
Indicator
PRT
FEMY
Relative Strength Index (RSI) 35.38 40.76
Support Level N/A $0.33
Resistance Level $3.57 $0.58
Average True Range (ATR) 0.13 0.05
MACD -0.03 -0.00
Stochastic Oscillator 8.41 45.56

Price Performance

Historical Comparison
PRT
FEMY

About PRT PermRock Royalty Trust Trust Units

PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: